NCT07680244Recruiting
(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000
Source: ClinicalTrials.gov · Last updated 28 Aug 2026
Brief summary (registry, in English)
This study will measure how well PathFinder 1.0 detects retinal abnormalities on macular cube OCT B-scans by assessing its sensitivity and specificity.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- First submitted
- 17 Jun 2026
- Start date
- 23 May 2025
- Primary completion date
- 31 Aug 2026
- Lead sponsor
- Carl Zeiss Meditec-Dublin CoCe
- Diseases
- Macular degeneration
- NCT number
- NCT07680244
What you commit to
- Study type: Interventional
- Planned participants: 400
- From 23 May 2025 to the primary completion date, 31 Aug 2026
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Inability to undergo the required tests.
- Unable to give consent or follow study instructions.
- Inability to fixate that precludes obtaining acceptable macula scans in the study eye.
- Visudyne (verteporfin) injection within the last 48 hours in the study eye.
- Pilocarpine or Vuity use within the last 24 hours in the study eye.
- Dense media opacity precluding adequate visualization of the retina in the study eye.
- Vitreous floaters that preclude obtaining acceptable scans in the study eye.
Who the study is looking for
- Able and willing to make the required study visits.
- Able and willing to give written informed consent and follow study instructions.
- Able and willing to complete ophthalmic imaging.
- Adults 18 years of age or older.
- The subject population will be comprised of two groups (all categories below pertain to the central 6x6 mm macula area):
- Group A
- 1\. Subjects with absence of macular abnormalities Group B
- Subjects with Disruption of the vitreoretinal interface (VRI)
- Subjects with Intraretinal hyporeflective space (IRHS)
- Subjects with Subretinal hyporeflective space (SRHS)
- Subjects with IS/OS (Ellipsoid Zone) disruption
- Subjects with Retinal Pigment Epithelium (RPE) elevation
- Subjects with Retinal Pigment Epithelium (RPE) atrophy
- Other abnormalities
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nova Southeastern University; College of Optometry Coordinator of this site? Confirm its status | Fort Lauderdale | United States | Recruiting |
| Moyes Eye Center Coordinator of this site? Confirm its status | Kansas City | United States | Recruiting |
| Northern California Retina Vitreous Associates Coordinator of this site? Confirm its status | Mountain View | United States | Recruiting |
| Eyecare Medical Group Coordinator of this site? Confirm its status | Portland | United States | Recruiting |
| Premier Eyecare of San Francisco Coordinator of this site? Confirm its status | San Francisco | United States | Completed |
| Retina Associates Coordinator of this site? Confirm its status | Tucson | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.